Baiji Shenzhou 1.1 drug bgb-3111 was accepted by CDE

Beigene was jointly founded by Wang Xiaodong, academician of the National Academy of Sciences, and John oyler, an American with rich management experience It focuses on the field of tumor immunotherapy Three of the 10 experimental drugs (innovative original drugs) on its R & D pipeline have entered the clinical trial stage, and bgb-3111, which was undertaken by CDE, is one of them Bgb-3111 is a Btk inhibitor At present, it has been proved that bgb-3111 has a good activity on B-cell malignant tumors, and has shown the potential to be superior to other Btk inhibitors in preclinical trials The other two drugs that entered the clinical trial were bgb-283 (BRAF inhibitor, phase I) and bgb-290 (PARP inhibitor, phase I) For these two targeted small molecule anticancer drugs, Baiji Shenzhou and Merck xuelano reached cooperation agreements in 2013 Merck obtained the development rights of the two drugs in markets outside China, with mileage of US $5 million and US $9 million respectively Among them, bgb-283 has applied for clinical application in China, and the latest queue number is 130 digits (as shown below) The biopharmaceutical company, which has entered the research and development of tumor immune drugs, completed a low-key financing of 450 million yuan in 2014, with funds from Hillhouse capital, the US dollar fund of CITIC Industrial Fund and a public investment fund from the United States focusing on life science and technology But this is just the beginning In the future, Baiji will accelerate its pace and complete the landing of Nasdaq stock market.